CD Genomics provides the newest CRISPR Cas9 sequencing service using next-generation sequencing (NGS) technology.
CRISPRs (clustered regularly interspaced short palindromic repeats) are DNA loci containing short repetitions of base sequences that are present within prokaryotes and function as a primitive immune system, cleaving foreign DNA (from invading viruses). CRISPRs have now been used as gene editing tools in mammalian systems. When paired with the Cas9 nuclease, CRISPRs can cleave genomic DNA in a site-specific manner, thus knocking out gene expression.
The rapid progress in developing Cas9 into a set of tools for cell and molecular biology research has been remarkable, likely due to the simplicity, high efficiency and versatility of the system. Cas9's potential reaches beyond DNA cleavage, and its usefulness for genome locus-specific recruitment of proteins will likely only be limited by our imagination.
In support of the scientific community's enthusiastic embracement of the CRISPR/Cas9 genome editing technology, CD Genomics has developed a cost-effective, high-throughput strategy for identifying CRISPR/Cas-induced mutations via deep sequencing.
|•||Low input DNA requirement|
|•||Cost-effective ultra-deep sequencing of PCR amplicons|
|•||Highly sensitive detection levels without bias|
|•||Without time-consuming cloning steps|
|•||Without universal tags on target-specific amplicons|
|•||Unambiguous Results: Deeper sequencing with amplicons and paired-end reads enables phasing of edit genome for more accurate, high-resolution typing.|
|•||Sample-to-Report Solution: Complete workflow includes primer design, library prep, sequencing, data analysis, and reporting|
• Raw data as FASTQ files via hard drive
• Discovery report
The service is offered for Research use only. Not for use in diagnostic procedures.